Drug
Liraglutide Pen Injector Saxenda
Liraglutide Pen Injector Saxenda: highest development phase Phase 3, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| Liraglutide Pen Injector [Saxenda] NCT03480022 | Phase 3 | Pre Diabetes |
Latest
No recent events.
Follow Liraglutide Pen Injector Saxenda on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.